Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality assessment and transfusion efficacy of buffy coat-derived platelet concentrates washed with platelet additive solution.
Fernández-Muñoz H, Castilla-Llorente C, Plaza EM, Martínez-Millán C, Heras I, Iniesta P, Amigo ML, Ferrer-Marin F, Candela MJ, Lozano ML, Vicente V, Rivera J. Fernández-Muñoz H, et al. Blood Transfus. 2018 May;16(3):273-278. doi: 10.2450/2017.0277-16. Epub 2017 Apr 13. Blood Transfus. 2018. PMID: 28488971 Free PMC article. Clinical Trial.
Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation.
Fernández-Muñoz H, Plaza EM, Rivera-Caravaca JM, Candela MJ, Romera M, De Arriba F, Lozano ML, Vicente V, Heras I, Castilla-Llorente C, Rivera J. Fernández-Muñoz H, et al. Hematology. 2018 Oct;23(9):712-718. doi: 10.1080/10245332.2018.1455434. Epub 2018 Mar 27. Hematology. 2018. PMID: 29582705 Free article.
Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of STAT3 mutations.
Muñoz-Ballester J, Chen-Liang TH, Hurtado AM, Heras I, de Arriba F, García-Malo MD, Iniesta P, Lozano ML, Nieto JB, Ortuño FJ, Osma Mdel M, Padilla J, Teruel-Montoya R, Vicente V, Castilla-Llorente C, Jerez A. Muñoz-Ballester J, et al. Br J Haematol. 2016 Mar;172(6):937-46. doi: 10.1111/bjh.13917. Epub 2016 Jan 5. Br J Haematol. 2016. PMID: 26728704 Free article.
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma.
López-Corral L, Caballero-Velázquez T, López-Godino O, Rosiñol L, Pérez-Vicente S, Fernandez-Avilés F, Krsnik I, Morillo D, Heras I, Morgades M, Rifon JJ, Sampol A, Iniesta F, Ocio EM, Martin J, Rovira M, Cabero M, Castilla-Llorente C, Ribera JM, Torres-Juan M, Moraleda JM, Martinez C, Vázquez A, Gutierrez G, Caballero D, San Miguel JF, Mateos MV, Pérez-Simón JA. López-Corral L, et al. Biol Blood Marrow Transplant. 2019 Sep;25(9):1703-1712. doi: 10.1016/j.bbmt.2019.04.026. Epub 2019 May 3. Biol Blood Marrow Transplant. 2019. PMID: 31054983 Free article. Clinical Trial.
Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience.
Gayoso J, Balsalobre P, Pascual MJ, Castilla-Llorente C, López-Corral L, Kwon M, Serrano D, Piñana JL, Herrera P, Ferrá C, Pascual C, Heras I, Montesinos P, Zabalza A, Bento L, Figuera A, Buño I, Díez-Martín JL. Gayoso J, et al. Bone Marrow Transplant. 2016 Oct;51(10):1307-1312. doi: 10.1038/bmt.2016.115. Epub 2016 May 9. Bone Marrow Transplant. 2016. PMID: 27159177 Free article.
Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time.
Parody R, Martino R, de la Cámara R, García-Noblejas A, Esquirol A, Garcia-Cadenas I, Villaescusa T, Caballero D, Rovira M, Fernandez-Avilés F, Marquez-Malaver FJ, Espigado I, Castilla-Llorente C, Heras I, Cabero MA, Cabrera JR, Barba P, Valcarcel D, Sánchez-Ortega I, Duarte RF, Serrano D, Carretero F, Vazquez L. Parody R, et al. Bone Marrow Transplant. 2015 Feb;50(2):274-81. doi: 10.1038/bmt.2014.229. Epub 2014 Oct 27. Bone Marrow Transplant. 2015. PMID: 25347007
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L, Sampol A, Caballero D, Serrano D, Heras I, San Miguel J, Pérez-Simón JA. Caballero-Velázquez T, et al. Br J Haematol. 2013 Aug;162(4):474-82. doi: 10.1111/bjh.12410. Epub 2013 Jun 15. Br J Haematol. 2013. PMID: 23772672 Free article. Clinical Trial.
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients.
Maillard A, Redjoul R, Klemencie M, Labussière Wallet H, Le Bourgeois A, D'Aveni M, Huynh A, Berceanu A, Marchand T, Chantepie S, Botella Garcia C, Loschi M, Joris M, Castilla-Llorente C, Thiebaut-Bertrand A, François S, Leclerc M, Chevallier P, Nguyen S. Maillard A, et al. Blood. 2022 Jan 6;139(1):134-137. doi: 10.1182/blood.2021014232. Blood. 2022. PMID: 34818411 Free PMC article. No abstract available.
60 results